- Home
- SNGX vs CHEK Comparison
SNGX vs CHEK Comparison
Compare SNGX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CHEK
- Stock Information
- Founded
- SNGX 1987
- CHEK 2004
- Country
- SNGX United States
- CHEK Israel
- Employees
- SNGX N/A
- CHEK N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- SNGX Health Care
- CHEK Health Care
- Exchange
- SNGX Nasdaq
- CHEK Nasdaq
- Market Cap
- SNGX 4.3M
- CHEK 4.5M
- IPO Year
- SNGX 1987
- CHEK 2015
- Fundamental
- Price
- SNGX $2.78
- CHEK $0.67
- Analyst Decision
- SNGX Strong Buy
- CHEK
- Analyst Count
- SNGX 1
- CHEK 0
- Target Price
- SNGX $6.00
- CHEK N/A
- AVG Volume (30 Days)
- SNGX 22.2M
- CHEK 26.5K
- Earning Date
- SNGX 08-14-2025
- CHEK 08-26-2025
- Dividend Yield
- SNGX N/A
- CHEK N/A
- EPS Growth
- SNGX N/A
- CHEK N/A
- EPS
- SNGX N/A
- CHEK N/A
- Revenue
- SNGX N/A
- CHEK N/A
- Revenue This Year
- SNGX N/A
- CHEK N/A
- Revenue Next Year
- SNGX N/A
- CHEK N/A
- P/E Ratio
- SNGX N/A
- CHEK N/A
- Revenue Growth
- SNGX N/A
- CHEK N/A
- 52 Week Low
- SNGX $1.09
- CHEK $0.56
- 52 Week High
- SNGX $5.40
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- SNGX 59.82
- CHEK 40.79
- Support Level
- SNGX $2.32
- CHEK $0.59
- Resistance Level
- SNGX $2.99
- CHEK $0.68
- Average True Range (ATR)
- SNGX 0.69
- CHEK 0.04
- MACD
- SNGX 0.02
- CHEK 0.00
- Stochastic Oscillator
- SNGX 38.10
- CHEK 46.45
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.